Tag: JR Rahn
MindMed streamlines leadership with further emphasis on integrating psychedelic drug development with digital medicines and therapeutics
J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on…
Recent Comments